Drug Trial Radar · NCT05060887
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
239
Actual
Start
Nov 15, 2021
Primary completion
Feb 1, 2022
Study completion Dec 7, 2022
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- Collaborators
- University Ghent
- First posted
- Sep 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 2a clinical trial is designed to evaluate the immunogenicity and the safety of one administration of OVX836 influenza vaccine at different dose levels (180µg, 300μg and 480μg) in order to assess the dose response of the OVX836 influenza vaccine.
Conditions
- Influenza
Interventions
OVX836-003Biological
One single administration intramuscularly at Day 1.
Saline solutionBiological
One single administration intramuscularly at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of NP-specific T-cell frequencies in peripheral blood, measured by IFNγ ELISPOT, at Day 8 versus pre-injection baseline (Day 1).Time frame: at Day 8 versus pre-injection baseline (Day 1)
- Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever)Time frame: during 7 days after vaccine administration
- Proportion of subjects reporting unsolicited Adverse EventsTime frame: during 29 days after vaccine administration
- Proportion of subjects with Influenza-Like-Illness cases associated with laboratory-confirmed influenzaTime frame: during the whole study duration, 180 days
- Severity scores of Influenza-Like-Illness cases (as per Flu-PRO® questionnaire)Time frame: during the whole study duration, 180 days
- Proportion of subjects reporting Serious Adverse EventsTime frame: during the whole study duration, 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Vaccinology (CEVAC)
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.